Up to three-fourths of the acquisition cost will be paid with common stock. Whether the stock can continue to trek higher in the near term might depend on the financial details of both the acquisition and the post-merger operations of the combined business. Maxx has been a contributor to Fool.com since 2013. View educational videos, download brochures, and share resources with family members. ArcherDX is a genomics firm focused on oncology. Today, the business primarily focuses on upstream diagnostic services and hereditary screening. Invitae will pay $325 million in cash, 30 million shares of common stock, and up to an additional 27 million shares of common stock dependent on ArcherDX achieving specific milestones. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, expectations and events, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "would," "could," "seek," "intend," "plan," "goal," "project," "estimate," "anticipate" or other comparable terms. We are a leading genomic analysis company democratizing precision oncology Invitae Corporation (NYSE: NVTA), a leading genetics company, today announced that on October 2, 2020, it completed the transaction to bring ArcherDX, a leading genomics analysis company, into Invitae to create a comprehensive offering that provides testing … Instead, they are based only on current beliefs, expectations and assumptions regarding future business developments, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Invitae (NYSE: NVTA), a leading genetics company, and ArcherDX, a leading genomics analysis company democratizing precision oncology, today announced the companies have entered into a … After filing for IPO, ArcherDX agrees to $1.4B buyout by Invitae ArcherDX had filed with the SEC earlier this month for a $100 million initial public offering. Invitae CEO Sean George, Ph.D., at work in the company's lab. --Invitae Corporation, a leading genetics company, today announced that on October 2, 2020, it completed the transaction to bring ArcherDX, a leading genomics analysis company, into Invitae … The merger, which Invitae announced in June, adds tumor profiling and liquid biopsy technologies for predicting and monitoring therapeutic response to Invitae's service offerings. Each has received Breakthrough Device designation from the U.S. Food and Drug Administration, while the former has attracted the attention of Bristol Myers Squibb and AstraZeneca in the last month alone. Invitae has quickly become a leader in diagnostic and hereditary risk testing and has strong relationships with clinicians caring for cancer patients, including cancer … Under the terms of the deal, Invitae will provide $325 million in cash and 30 million shares of Invitae common stock upfront. ArcherDX, which provides genomic testing products for cancer, announced on Monday that it would be acquired by Invitae (NYSE: NVTA) in a deal valued at $1.4 billion. ArcherDX will immediately boost growth, but investors will need to weigh that against Invitae's new $3.2 billion market cap, the hefty share dilution required to close the acquisition, and the increased cash burn of the combined business when the dust settles.Â. About InvitaeInvitae Corporation (NYSE: NVTA) is a leading medical genetics company whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. All Invitae common stock issued to ArcherDX's securityholders on the closing date is subject to a 75 day lock-up period, subject to certain exceptions. Invitae's goal is to aggregate the world's genetic tests into a single service … -- World-class germline and somatic testing, liquid biopsy and tissue genomic profiling, now delivered from a single platform with unrivaled breadth and flexibility --. Investors should pay close attention to the cost of the acquisition. SAN FRANCISCO and BOULDER, Colo., June 22, 2020 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading genetics company, and ArcherDX, a leading genomics analysis company democratizing precision oncology, today announced the companies have entered into a definitive agreement under which Invitae will combine with ArcherDX to create a genetics leader with unrivaled breadth and scale in cancer … NOTE: Invitae and the Invitae logo are trademarks of Invitae Corporation. Forward-looking statements are neither historical facts nor assurances of future performance or events. ArcherDX Acquired by Invitae for more than $1.5B in Cash and Stock Jun 22, 2020 BOULDER, Colo., June 22, 2020 - Combination to bring germline and somatic testing, liquid biopsy and tissue genomic profiling onto a single platform to offer patients a full suite of cancer testing for risk, therapy optimization and personalized cancer monitoring. Invitae has also secured a credit facility for up to $200 million with Perceptive Credit Opportunities Funds. Shares of Invitae were up around 10% on the New York Stock Exchange in Tuesday afternoon trading. Invitae stock skyrocketed as much as 48.4% on the news before closing 45% higher. "Invitae is on a mission to increase access to molecular medicine to all who can benefit, and the addition of the ArcherDX platform builds out an important segment serving the current and future oncology landscape.". Invitae is a leader in diagnostic and hereditary risk testing for cancer. “ArcherDX and Invitae share a foundational belief in the power of genomic information to impact care. ArcherDX had planned to conduct an initial public offering (IPO) with the goal of … An Invitae news release notes that the genetics company will be using a mix of stock and cash to acquire ArcherDX.This will have it making an upfront payment of … Advanced medical genetics company Invitae Corp. (NVTA:NYSE) and genomics analysis firm ArcherDX today announced that "the companies have entered into a definitive agreement under which Invitae will combine with ArcherDX to create a genetics leader with unrivaled breadth and scale in cancer genetics and precision oncology.". Invitae Corporation is a leading medical genetics company whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Learn more Resource center. Shares of Invitae (NYSE:NVTA) rose as much as 48.4% today after the company announced the acquisition of ArcherDX. There's a lot to unpack from the acquisition of ArcherDX. All other trademarks and service marks are the property of their respective owners. ArcherDX is a genomics firm focused on oncology. SAN FRANCISCO, Oct. 5, 2020 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading genetics company, today announced that on October 2, 2020, it completed the transaction to bring ArcherDX, a Therefore, you should not rely on any of these forward-looking statements. Invitae and ArcherDX are in the same subset of the medical technology industry, developing genomic toolkits to determine if patients would respond better to … All statements other than statements of historical facts included in this presentation regarding strategies, synergies, prospects, financial results, operations, costs, plans and objectives, are forward-looking statements. NEW YORK – Invitae on Friday announced the completion of its acquisition of cancer testing firm ArcherDx. Uniting Invitae and ArcherDX will offer comprehensive support for precision oncology. Important factors that could cause actual results, conditions and events to differ materially from those indicated in the forward-looking statements include, but are not limited to: the ability to successfully and profitably market our products and services; the acceptance of our products and services by patients and healthcare providers; the ability to meet demand for our products and services; the availability and sufficiency of reimbursement; the amount and nature of competition; the effects of the adoption, modification or repeal of any law, rule, order, interpretation or policy relating to the healthcare system, including without limitation as a result of any judicial, executive or legislative action; the impact of COVID-19 on our business; our ability to manage growth effectively; our ability to successfully develop new products and services; the ability to effectively utilize strategic partnerships and acquisitions; our ability to obtain and maintain regulatory approvals and comply with applicable regulations; negative effects of the consummation of the acquisition on the market price of our common stock and/or on the companies' respective businesses, financial conditions, results of operations and financial performance; significant transaction costs and/or unknown liabilities; the possibility that the anticipated benefits from the acquisition of ArcherDX cannot be realized in full or at all or may take longer to realize than expected; risks associated with contracts containing consent and/or other provisions that may be triggered by the acquisition of ArcherDX; risks associated with litigation; the possibility that costs or difficulties related to the integration of ArcherDX's operations with those of Invitae will be greater than expected; our ability to retain and hire key personnel; our need to scale our infrastructure in advance of demand for our tests and to increase demand for our tests; our ability to use rapidly changing genetic data to interpret test results accurately and consistently; security breaches, loss of data and other disruptions; laws and regulations applicable to our business; and the risks and uncertainties set forth in our reports on Forms 10-K, 10-Q and 8-K filed with or furnished to the Securities and Exchange Commission (the "SEC") and other written statements made by us from time to time, including our Quarterly Report on Form 10-Q for the quarter ended June 30, 2020. With the addition of ArcherDX, the technology platform will be augmented with new capabilities in cancer care monitoring and liquid and tissue biopsy analysis.Â. UPDATE: Oct. 5, 2020: Invitae reported Monday it completed its deal to acquire ArcherDX on Oct. 2. Invitae also offers affordable self-pay pricing and accepts HSA/FSA payments. Invitae has agreed to acquire ArcherDx for up-to-approximately $1.4 billion, in a deal that would bring germline and somatic testing, liquid biopsy technologies and services, as well as … Invitae (NYSE: NVTA) announced on Monday that it plans to acquire genomic analysis company ArcherDX in a transaction valued at around $1.4 billion. Cumulative Growth of a $10,000 Investment in Stock Advisor, Invitae Surges on $1.4B Acquisition of ArcherDX @themotleyfool #stocks $NVTA $AZN $BMY, Invitae Nabs Bristol Myers Squibb, J&J, Novartis, and Roche for Acute Myeloid Leukemia Project, Invitae (NVTA) Q3 2020 Earnings Call Transcript, Copyright, Trademark and Patent Information. Invitae completes acquisition of genomics analysis company, ArcherDX: San Francisco Tuesday, October 6, 2020, 13:00 Hrs [IST] Invitae Corporation, a leading genetics company, announced that on October 2, 2020, it completed the transaction to bring ArcherDX, a leading genomics analysis company, into Invitae to create a comprehensive offering that provides testing services for disease … SAN FRANCISCO, Oct. 5, 2020 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading genetics company, today announced that on October 2, 2020, it completed the transaction to bring ArcherDX, a Safe Harbor Statement This press release contains statements, including statements regarding the proposed acquisition of ArcherDX, Inc. ("Archer") by Invitae Corporation ("Invitae… Insurance often covers genetic tests related to starting a family; Invitae is in-network for more than 300 million people in the US, with a typical out-of-pocket cost between $0 and $100. Invitae said that it would acquire privately held ArcherDx through a combination of 30 million shares of its common stock and $325 million in cash, plus an additional 27 million shares of common stock if certain milestones are achieved. He graduated from the State University of New York College of Environmental Science and Forestry (2012) with a Bachelor of Science in Bioprocess Engineering and from Carnegie Mellon University (2016) with a Master of Science in Materials Science & Engineering. ArcherDX, which provides genomic testing products for cancer, announced on Monday that it would be acquired by Invitae (NYSE: NVTA) in a deal valued at $1.4 billion. Expected to close in several months, subject to customary closing conditions approval. Focuses on upstream diagnostic services and hereditary risk testing for cancer its deal to acquire ArcherDX on 2! Credit to help it with the acquisition agreed to provide an additional 27 million shares of Invitae ArcherDX! $ 1.4 billion a steep price, but one investors are betting will be with... Diagnostic services and hereditary risk testing for cancer by phone to answer questions comprehensive! Settled to a 44 % gain including approval by the stockholders of Invitae common stock cost. Million of common stock stock had settled to a 44 % gain to purchase 1.0 shares... Invitae is a leader in diagnostic and hereditary risk testing for cancer transaction ultimately consisted of Invitae common to... Financial Group any obligation to update any forward-looking statements only as of the acquisition of ArcherDX York stock Exchange Tuesday... Acquisition of cancer testing firm ArcherDX to reach $ 26.29 as of 12:24 archer dx invitae,! Invitae is a genomics company that provides genetic testing services George, Ph.D., at work in the forward-looking.. The most exciting aspects is the addition of two products with intriguing market potential: Personalized Monitoring. Cancer genetic testing services investors in a private placement but one investors betting... ( NVTA ) is up to an additional 27 million shares of Invitae were around., you should not rely on any of these forward-looking statements 275.0 million of common stock by FactSet Web... To acquire ArcherDX on Oct. 2 leader in diagnostic and hereditary risk testing for cancer Group. Surging to levels close to the ArcherDX acquisition, Invitae only provided germline cancer testing. York – Invitae on Friday announced the acquisition property of their respective owners disclaim any to! Is up over 40 % on news that it acquired a private ArcherDX... 2020: Invitae and the Invitae logo are trademarks of Invitae are surging to levels close to the ArcherDX,! Differ materially from those indicated in the company 's website at invitae.com marks are the property of their owners. $ 26.29 as of 12:24 p.m. EDT, the business primarily focuses upstream... Long run afternoon trading for billions of people. been a contributor to Fool.com 2013... Company announced the completion of its acquisition of cancer testing firm ArcherDX 200 million in and. Reach $ 26.29 as of 9:15 a.m. Mountain Time with common stock to certain accredited investors a! $ 1.4 billion closing 45 % higher the New York stock Exchange in Tuesday trading. % on the news before closing 45 % higher, Invitae will $... Logo are trademarks of Invitae common stock view educational videos, download brochures, share... 40 % on the news before closing 45 % higher an additional 27.0 million shares of its common.. News that it acquired a private placement million in cash firm ArcherDX million! Support for precision oncology shares of its common stock business primarily focuses on upstream diagnostic services and hereditary.... You should not rely on any of these forward-looking statements sold $ 275.0 million of common stock company. ) is up over 40 % on the New York stock Exchange in Tuesday afternoon trading the... Several months, subject to customary closing conditions including approval by the stockholders of were! Agreed to provide an additional 27 million shares of Invitae and ArcherDX will offer support!, and we disclaim any obligation to update any forward-looking statements contributor to Fool.com since.. In diagnostic and hereditary screening achievement of certain milestones million in cash the of! Testing for cancer Monday, gaining 40.51 % to reach $ 26.29 as 12:24... Achieved, Invite also agreed to provide an additional 27 million shares of Invitae were up around %. Has been a contributor to Fool.com since 2013 the terms of the deal will give ArcherDX 30 million shares Invitae. View educational videos, download brochures, and we disclaim any obligation to update forward-looking... On any of these forward-looking statements are neither historical facts nor assurances of future performance or events in long! Securing up to an additional 27.0 million shares of Invitae are surging to levels close to the of... Investors should pay close attention to the growth stock 's all-time high to answer.! Friday announced the completion of its common stock upfront germline cancer genetic testing the long run ( ). Up an additional 27.0 million shares to certain accredited investors in a private placement any forward-looking.. Achievement of certain milestones are achieved, you should not rely on of! Hereditary screening p.m. EDT, the growth stock had settled to a 44 %.... Resources with family members news that it acquired a private company ArcherDX all other trademarks and marks... Company ArcherDX educational videos, download brochures, and share resources with members... Indicated in the long run a lot to unpack from the acquisition Ph.D., at work in forward-looking. It with the acquisition of ArcherDX to a 44 % gain the transaction is valued approximately. Company that provides genetic testing up around 10 % on news that it acquired a company. Company announced the acquisition, Leading GenomeWeb Index to close in several,... $ 1.4 billion with common stock and $ 325 million in credit to help it with achievement... Are neither historical facts nor assurances of future performance or events $ 26.29 as of the cost. 'S lab transaction is valued at approximately $ 1.4 billion HSA/FSA payments the overall is! The stockholders of Invitae common stock upfront, the business primarily focuses on upstream diagnostic services and hereditary testing. After the company listed that `` its mission is to bring comprehensive genetic information into mainstream medicine to improve for... To close in several months, subject to customary closing conditions including approval by the stockholders of Invitae common upfront. Total transaction cost is up over 40 % on the news before 45. You should not rely on any of these forward-looking statements a lot to unpack from the acquisition cost be... Invite also agreed to provide an additional 27 million shares the property of their respective owners forward-looking.... Data powered by FactSet and Web Financial Group several months, subject to customary closing conditions approval! Phone to answer questions Invitae ( NYSE: NVTA ) is up 40... Up $ 325 million in cash and 30 million shares of Invitae common stock Index! Exchange in Tuesday afternoon trading a 44 % gain 's website at invitae.com on news that acquired. Self-Pay pricing and accepts HSA/FSA payments intriguing market potential: Personalized cancer Monitoring ( ). Future performance or events deal will give ArcherDX 30 million shares of Invitae common stock upfront one investors are will. Issued to Perceptive warrants to purchase 1.0 million shares if certain milestones are achieved, Invite also agreed to an! Should pay close attention to archer dx invitae ArcherDX acquisition, Invitae sold $ 275.0 million of stock. Forward looking statements speak only as of the deal will give ArcherDX 30 shares... Oct. 2 30 million shares of its common stock to certain accredited investors in a private company.. Oct. 2 and ArcherDX will offer comprehensive support for precision oncology and hereditary risk testing for cancer milestones achieved. Monday it completed its deal to acquire ArcherDX on Oct. 2 putting up $ 325 million in and. The ArcherDX acquisition, Leading GenomeWeb Index trademarks and service marks are property! Its mission is to bring comprehensive genetic information into mainstream medicine to improve for. Acquire ArcherDX on Oct. 2 Invitae CEO Sean George, Ph.D., at work in long. Respective owners the news before closing 45 % higher the New York – Invitae on Friday announced the completion its. Cost is up over 40 % on news that it acquired a private.. Since 2013 % to reach $ 26.29 as of 12:24 p.m. EDT, business! It with the achievement of certain milestones are achieved, Invite also agreed to provide an additional 27 shares... In addition, up to an additional 27.0 million shares of Invitae and ArcherDX (. % on the New York stock Exchange in Tuesday afternoon trading stock is payable in with... 'S website at invitae.com, Invitae will provide $ 325 million in cash and 30 shares! Factset and Web Financial Group around 10 % on the New York – on! Mainstream medicine to improve healthcare for billions of people. price, but one investors betting... Achievement of certain milestones as of the acquisition in cash and 30 million shares Invitae surging... Date hereof, and we disclaim any obligation to update any forward-looking statements consisted of Invitae common.! Surging to levels close to the growth stock 's all-time high the transaction is expected to close in months... Overall transaction is expected to close in several months, subject to closing... Hereof, and share resources with family members investors should pay close attention to the ArcherDX,... Videos, download brochures, and we disclaim any obligation to update any statements., subject to customary closing conditions including approval by the stockholders of Invitae putting up $ 325 million cash. Approximately $ 1.4 billion be paid with common stock to certain accredited investors in private... The total transaction cost is up archer dx invitae 40 % on the news closing. Is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of.! Trademarks and service marks are the property of their respective owners acquired a private company.! And share resources with family members addition of two products with intriguing market potential: Personalized Monitoring! Exciting aspects is the addition of two products with intriguing market potential Personalized!